Olanzapine and delirium: lesson from clinical  practice.
Singh
Dhiren
D
Forlano
Rosaria
R
D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis; D014151:Anti-Anxiety Agents / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D003693:Delirium / Q000139:chemically induced* / Q000175:diagnosis; D003866:Depressive Disorder / Q000188:drug therapy*; D003937:Diagnosis, Differential; D003987:Dibenzothiazepines / Q000008:administration & dosage; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D008297:Male; D000077152:Olanzapine; D010076:Oxazepam / Q000008:administration & dosage; D011618:Psychotic Disorders / Q000188:drug therapy*; D000069348:Quetiapine Fumarate; D013610:Tachycardia / Q000139:chemically induced
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D010076:Oxazepam; D000077152:Olanzapine